Clinical Trials Logo

Hyperkinesis clinical trials

View clinical trials related to Hyperkinesis.

Filter by:

NCT ID: NCT00152035 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Safety of SPD465 in Treating Adults With ADHD.

Start date: March 10, 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of SPD465 in the treatment of ADHD. The study will also look at how SPD465 affects sleep.

NCT ID: NCT00152022 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.

Start date: April 25, 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects the participants sleep and how they perceive their quality of life.

NCT ID: NCT00152009 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

Start date: January 29, 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17

NCT ID: NCT00151996 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Start date: August 16, 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of administering SPD503 (Guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of ADHD in children and adolescents aged 6-17

NCT ID: NCT00151970 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.

NCT ID: NCT00151957 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials

Start date: October 2004
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety of MTS in the symptomatic treatment of children aged 6-12 diagnosed with ADHD

NCT ID: NCT00150618 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

Start date: March 30, 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.

NCT ID: NCT00150592 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

Start date: May 12, 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.

NCT ID: NCT00150579 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Efficacy and Safety of SPD465 in Adults With ADHD

Start date: January 27, 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects sleep and how the participants perceive their quality of life.

NCT ID: NCT00142961 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

Start date: October 2005
Phase: Phase 2
Study type: Interventional

Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment for marijuana dependence. The purpose of this study is to determine the use of atomoxetine in treating adolescents who abuse marijuana and have ADHD. In addition, this study will assess whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will determine whether atomoxetine improves treatment retention and progress in adolescents with ADHD and marijuana dependence.